Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CRT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    148 result(s) found for: CRT. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2016-001456-21 Sponsor Protocol Number: B9991016 Start Date*: 2017-05-09
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN...
    Medical condition: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IE (Completed) PT (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005920-39 Sponsor Protocol Number: UC-IMM-2106 Start Date*: 2022-07-12
    Sponsor Name:Unicancer
    Full Title: A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT)
    Medical condition: Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously un...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002308-24 Sponsor Protocol Number: NWHHT 08-01 Start Date*: 2008-10-23
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A RANDOMISED STUDY OF DOCETAXEL/CISPLATIN/5-FLUOROURACIL (TPF) AS NEOADJUVANT CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY (CRT) WITH CONVENTIONAL RADIOTHERAPY (RT) VERSUS CONCOMITANT CRT...
    Medical condition: locally advanced HNSCC
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000076-33 Sponsor Protocol Number: UMCNONCO201007 Start Date*: 2011-11-15
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: Efficacy and Cost Efficacy of Prophylactic treatment with Antibiotics during concomitant chemoradiotherapy in patients with locally advanced head and neck cancer to prevent Aspiration Pneumonia.
    Medical condition: Patients with LAHNC which will be treated with chemoradiotherapy, as primary treatment or as postoperative treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000258-64 Sponsor Protocol Number: D1449L00004 Start Date*: 2005-04-08
    Sponsor Name:AstraZeneca AB
    Full Title: SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Co...
    Medical condition: Schizophrenia is a chronic psychiatric disorder that often begins during adolescence or early adulthood. A major problem for patients with schizophrenia is a cognitive deficit compared to a control...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002300-27 Sponsor Protocol Number: SPON1529-16 Start Date*: 2019-09-13
    Sponsor Name:Cardiff University
    Full Title: Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus
    Medical condition: Locally advanced (stage IIIA/B, T3/T4, any N,M0) anal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061424 Anal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003934-25 Sponsor Protocol Number: 3475-412 Start Date*: 2017-03-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous...
    Medical condition: Locally advanced head and neck squamous cell carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004420-15 Sponsor Protocol Number: M21IDB Start Date*: 2021-11-30
    Sponsor Name:NKI-AVL
    Full Title: A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)
    Medical condition: Urothelial cell carcinoma of the bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004161-68 Sponsor Protocol Number: AG013-ODOM-201 Start Date*: 2018-10-31
    Sponsor Name:Oragenics, Inc.
    Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance...
    Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004430-15 Sponsor Protocol Number: GS-US-356-0101 Start Date*: 2014-10-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Def...
    Medical condition: Subjects with an ICD or CRT-D implanted for primary or secondary prevention
    Disease: Version SOC Term Classification Code Term Level
    17.1 10007541 - Cardiac disorders 10047281 Ventricular arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) DK (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002589-30 Sponsor Protocol Number: CHUBX2015/17 Start Date*: 2018-01-29
    Sponsor Name:CHU DE BORDEAUX
    Full Title: Dynamic Contrast enhanced ultrasound for predict and assess rectal cancer response after neo-adjuvant chemoradiation – RECT
    Medical condition: Rectal Cancer
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004397-34 Sponsor Protocol Number: D933KC00001 Start Date*: 2018-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Adv...
    Medical condition: Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012453-38 Sponsor Protocol Number: Start Date*: 2009-09-14
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: A two-stage multicenter phase II trial of concurrent panitumumab immunotherapy, cisplatin chemotherapy and pelvic radiotherapy for primary cancer of the uterine cervix stage Ib-IIIb
    Medical condition: primary cancer of the uterine cervix stage Ib-IIIb
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002526-43 Sponsor Protocol Number: 150998-001 Start Date*: 2012-01-30
    Sponsor Name:Allergan Limited
    Full Title: Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration
    Medical condition: Exudative Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019071-29 Sponsor Protocol Number: 006/09 Start Date*: 2010-07-26
    Sponsor Name:BioVex, Inc.
    Full Title: A Phase 3 Randomized Trial of Concurrent Cisplatin And Radiotherapy With or Without OncoVEXGM-CSF in Previously Untreated Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041823 Squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002581-14 Sponsor Protocol Number: DvL-2020-01 Start Date*: 2020-11-04
    Sponsor Name:Medical University of Graz, Division of Cardiology
    Full Title: Ertugliflozin to Reduce Arrhythmic burden in ICD/CRT patientS (ERASe-Trial) – a phase III Study
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000392-14 Sponsor Protocol Number: 1200.131 Start Date*: 2011-07-27
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: LUX-Head & Neck 2 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary...
    Medical condition: Loco-regionally advanced head and neck squamous cell carcinoma with no evidence of disease after chemo-radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DE (Completed) FI (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IT (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000999-11 Sponsor Protocol Number: MNPR-301-001 Start Date*: 2021-09-23
    Sponsor Name:Monopar Therapeutics Inc.
    Full Title: A Phase 2b/3, multicenter, randomized, double-blind, placebocontrolled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induce...
    Medical condition: Chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000581-23 Sponsor Protocol Number: CSPP100A2244 Start Date*: 2008-07-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema
    Medical condition: Diabetic Macular Edema (DME) in hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001327-41 Sponsor Protocol Number: IMIB-RMV-2021-02 Start Date*: 2021-07-12
    Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia
    Full Title: Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized study
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 14:33:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA